Canaccord Genuity Maintains Hold and Raises Price Target on ISIS Pharmaceuticals (ISIS)

Today analysts at Canaccord Genuity maintained a Hold rating on ISIS Pharmaceuticals (NASDAQ: ISIS) and raised their price target to $11.00 (from $9.00). The increased PT ascribes greater value to the company's pipeline.

"We continue to view ISIS's pipeline as progressing nicely, with the next lead product, TTR (TTR amyloidosis, partnered with GSK) to enter P3 for familial polyneuropathy in H2," said analyst Salveen Richter.

For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.

Shares of ISIS Pharmaceuticals closed at $13.19 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Amazon.com (AMZN) PT Raised to $215 at UBS
• Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) PT Raised to JPY18,800 at Nomura/Instinet